Answers are grounded in this paper and cite their sources.
95 DTC patients without a diagnosis of DMT2 (group 1), in whom metformin was started, 79 non-diabetics DTC patients who did not start metformin (group 2) served as a control group. All subjects were evaluated at the baseline and after 12 and 24 months. Group 1 was also evaluated at 3 months and 36 month to assess the tolerability of metformin and then the therapy compliance.
No takes yet. Share an insight, caveat, or question.
Monti et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: